Cargando…

Activation of MAT2A-RIP1 signaling axis reprograms monocytes in gastric cancer

BACKGROUND: The activation of tumor-associated macrophages (TAMs) facilitates the progression of gastric cancer (GC). Cell metabolism reprogramming has been shown to play a vital role in the polarization of TAMs. However, the role of methionine metabolism in function of TAMs remains to be explored....

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yan, Yang, Hui, Zhao, Jun, Wan, Ping, Hu, Ye, Lv, Kun, Hu, YiRen, Yang, Xi, Ma, Mingzhe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7888314/ https://www.ncbi.nlm.nih.gov/pubmed/33593829 http://dx.doi.org/10.1136/jitc-2020-001364

Ejemplares similares

Correction: Activation of MAT2A-RIP1 signaling axis reprograms monocytes in gastric cancer
Publicado: (2021)

Correction: Activation of MAT2A-RIP1 signaling axis reprograms monocytes in gastric cancer
Publicado: (2021)

GPC2 antibody–drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies
por: Pascual-Pasto, Guillem, et al.
Publicado: (2022)

Divergent tumor and immune cell reprogramming underlying immunotherapy response and immune-related adverse events in lung squamous cell carcinoma
por: Chen, Minjiang, et al.
Publicado: (2023)

Predicting anti-PD-1 responders in malignant melanoma from the frequency of S100A9+ monocytes in the blood
por: Rad Pour, Soudabeh, et al.
Publicado: (2021)

Systemic infusion of TLR3-ligand and IFN-α in patients with breast cancer reprograms local tumor microenvironments for selective CTL influx
por: Gandhi, Shipra, et al.
Publicado: (2023)

Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy
por: Schetters, Sjoerd T T, et al.
Publicado: (2020)

Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages
por: Ou, Da-Liang, et al.
Publicado: (2021)

Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis
por: Franken, Amelie, et al.
Publicado: (2022)

Targeting resistance to radiation-immunotherapy in cold HNSCCs by modulating the Treg-dendritic cell axis
por: Knitz, Michael W, et al.
Publicado: (2021)

High endothelial venule is a surrogate biomarker for T-cell inflamed tumor microenvironment and prognosis in gastric cancer
por: Park, Hyung Soon, et al.
Publicado: (2021)

Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer
por: Kwon, Minsuk, et al.
Publicado: (2022)

Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC
por: Li, Kun, et al.
Publicado: (2022)

Selective targeting of GARP-LTGFβ axis in the tumor microenvironment augments PD-1 blockade via enhancing CD8(+) T cell antitumor immunity
por: Li, Anqi, et al.
Publicado: (2022)

WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape
por: Lu, Chunwan, et al.
Publicado: (2021)

Visual analysis of global research on immunotherapy for gastric cancer: A literature mining from 2012 to 2022
por: Chen, Yizhen, et al.
Publicado: (2023)

Control of PD-L1 expression in CLL-cells by stromal triggering of the Notch-c-Myc-EZH2 oncogenic signaling axis
por: Böttcher, Martin, et al.
Publicado: (2021)

Interferon gamma inhibits CXCL8–CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer
por: Zhang, Mingjie, et al.
Publicado: (2020)

Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial
por: Zhang, Wenwen, et al.
Publicado: (2023)

Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade
por: Randon, Giovanni, et al.
Publicado: (2023)

Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy
por: Gao, Hannan, et al.
Publicado: (2020)

Immune checkpoint blocking impact and nomogram prediction of COVID-19 inactivated vaccine seroconversion in patients with cancer: a propensity-score matched analysis
por: Ma, Yifei, et al.
Publicado: (2021)

Intratumoral IL-1R1 expression delineates a distinctive molecular subset with therapeutic resistance in patients with gastric cancer
por: Zhang, Puran, et al.
Publicado: (2022)

MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer
por: Wu, Si-Yu, et al.
Publicado: (2021)

PER2 binding to HSP90 enhances immune response against oral squamous cell carcinoma by inhibiting IKK/NF-κB pathway and PD-L1 expression
por: Zhang, Zhiwei, et al.
Publicado: (2023)

Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)
por: Yang, Yunpeng, et al.
Publicado: (2021)

Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study
por: Yoshikawa, Akie Kimura, et al.
Publicado: (2022)

Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL
por: Song, Fengmei, et al.
Publicado: (2023)

Adding liposomal doxorubicin enhances the abscopal effect induced by radiation/αPD1 therapy depending on tumor cell mitochondrial DNA and cGAS/STING
por: Wang, Liqun, et al.
Publicado: (2023)

FimH confers mannose-targeting ability to Bacillus Calmette-Guerin for improved immunotherapy in bladder cancer
por: Zhang, Yang, et al.
Publicado: (2022)

HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial
por: Song, Yan, et al.
Publicado: (2020)

Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial
por: Shitara, Kohei, et al.
Publicado: (2023)

Peptidic microarchitecture-trapped tumor vaccine combined with immune checkpoint inhibitor or PI3Kγ inhibitor can enhance immunogenicity and eradicate tumors
por: Du, Yang, et al.
Publicado: (2022)

Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response
por: Qi, Xiaoqiang, et al.
Publicado: (2020)

Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity
por: Chen, Dawei, et al.
Publicado: (2020)

Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors
por: Ma, Yuxiang, et al.
Publicado: (2023)

Infiltrating pattern and prognostic value of tertiary lymphoid structures in resected non-functional pancreatic neuroendocrine tumors
por: Zhang, Wu-Hu, et al.
Publicado: (2020)

Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma
por: He, Xiran, et al.
Publicado: (2020)

Personalized neoantigen vaccine combined with PD-1 blockade increases CD8(+) tissue-resident memory T-cell infiltration in preclinical hepatocellular carcinoma models
por: Chen, Hengkai, et al.
Publicado: (2022)

Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial
por: Xie, Lu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_n8vdcp5bar42h0ecvi0npm8spj